These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 86623

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Clinical experiences with pepleomycin (NK 631) (author's transl)].
    Kusakari J, Sato Y, Saijo S, Tomioka S, Kawamoto K.
    Jpn J Antibiot; 1978 Nov; 31(11):659-63. PubMed ID: 83402
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Clinical experience with NK 631 in malignant tumors of skin (author's transl)].
    Nobe O, Kubo H, Yoshii K, Tashiro M.
    Jpn J Antibiot; 1979 Mar; 32(3):463-9. PubMed ID: 86628
    [Abstract] [Full Text] [Related]

  • 6. [Histological appearances of cancer of the head and neck treated with pepleomycin (NK 631) (author's transl)].
    Matsumura Y, Nomura Y, Eguchi S, Yanagita T.
    Jpn J Antibiot; 1978 Nov; 31(11):651-8. PubMed ID: 83401
    [Abstract] [Full Text] [Related]

  • 7. [Results with the cytostatic agent bleomycin in tumour therapy (author's transl)].
    Baumgartner G.
    Wien Klin Wochenschr; 1973 Oct 19; 85(42):686-92. PubMed ID: 4128921
    [No Abstract] [Full Text] [Related]

  • 8. [Clinical experience with NK 631 (pepleomycin) for malignant tumors of skin (author's transl)].
    Seki T, Shimada S, Ohara K.
    Jpn J Antibiot; 1979 Feb 19; 32(2):278-81. PubMed ID: 86624
    [No Abstract] [Full Text] [Related]

  • 9. Discovery of clinical effect of bleomycin and its further development.
    Ichikawa T.
    Prog Biochem Pharmacol; 1976 Feb 19; 11():143-57. PubMed ID: 63959
    [No Abstract] [Full Text] [Related]

  • 10. Controlled studies with bleomycin in solid tumors and lymphomas.
    Bonadonna G, Tancini G, Bajetta E.
    Prog Biochem Pharmacol; 1976 Feb 19; 11():172-84. PubMed ID: 63961
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Clinical effects of NK 631 in malignant tumors of the oral cavity (author's transl)].
    Kawahira K, Dohhara Y, Sugihara K, Yamada K, Fujinami Y, Saku T, Yamashita S.
    Jpn J Antibiot; 1979 Jan 19; 32(1):138-48. PubMed ID: 84884
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Clinical effects of NK 631, a new bleomycin derivative, in treatment of oral cancer (author's transl)].
    Kajiyama M, Dohjyo M, Ohno A, Nagasaka K, Yamaguma M, Okabe T, Terasaka S.
    Jpn J Antibiot; 1979 Jan 19; 32(1):129-37. PubMed ID: 84883
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase II evaluation of bleomycin. A Southwest oncology Group study.
    Haas CD, Coltman CA, Gottlieb JA, Haut A, Luce JK, Talley RW, Samal B, Wilson HE, Hoogstraten B.
    Cancer; 1976 Jul 19; 38(1):8-12. PubMed ID: 59628
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Current status of PEP bleomycin studies in Japan.
    Ikeda S, Miyasato H, Nakayama H, Tajima K, Sato A.
    Recent Results Cancer Res; 1981 Jul 19; 76():41-60. PubMed ID: 6165056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.